Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORT-77 in Healthy Adult Participants
NCT06346509Phase 1Completed
- Sponsor
- Portal Therapeutics
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing PORT-77 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events at Day 21. Started Apr 2024; status: completed.
02
Drugs
port-77
Beyond the preview
Go deeper on NCT06346509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346509.